Mechanism of action
Dual GIP/GLP-1 Agonism
Also called twincretin, dual incretin agonist
Activating two incretin receptors, GIP and GLP-1, for greater metabolic effect than GLP-1 alone.
Medically reviewed by Dr. Jonathan Snipes, MD
Reviewed for clinical accuracy · Last reviewed July 22, 2026 · Review policy
Quick answer
Dual GIP/GLP-1 agonism means activating two incretin receptors at once, GIP and GLP-1, rather than GLP-1 alone. Combining the two pathways enhances insulin response, slows gastric emptying, and reduces appetite more strongly, which is why tirzepatide produced greater weight loss than pure GLP-1 drugs in trials.
Key takeaways
- →GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone alongside GLP-1.
- →Activating both receptors appears to produce greater metabolic and weight effects than GLP-1 alone.
- →Tirzepatide is the first FDA-approved dual GIP/GLP-1 agonist.
- →The larger trial weight loss (up to ~21%) is the main clinical signal of the added GIP action.
What it is
The incretin system has two main hormones: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). A dual GIP/GLP-1 agonist, sometimes called a twincretin, activates both receptors with a single molecule, rather than targeting GLP-1 alone.
How it works
By engaging both incretin receptors, a dual agonist amplifies the same core effects, glucose-dependent insulin secretion, slowed gastric emptying, and appetite reduction, while GIP activity appears to contribute additional metabolic benefits. The clinical evidence for the combined approach is the larger average weight loss seen in tirzepatide's trials compared with pure GLP-1 agents, though the two were tested in separate studies.
Compounds that use this mechanism
Frequently asked questions
Why is dual GIP/GLP-1 agonism more effective?+
Activating both incretin receptors appears to enhance insulin response and appetite reduction beyond GLP-1 alone, which is the leading explanation for tirzepatide's larger trial weight loss.
What drug uses this mechanism?+
Tirzepatide (Mounjaro, Zepbound) is the first FDA-approved dual GIP/GLP-1 receptor agonist.
Sources
- 1.Drugs@FDA: FDA-Approved Drugs database · U.S. Food & Drug Administration